Febit Announces Restructuring
The restructuring will close down febit’s instrument business and end sales of microfluidic chips that are not used as part of a service offering (see IBO 4/15/10). Mass High Tech reported that the workforce reduction will affect approximately 60 employees.
Heidelberg, Germany and Lexington, MA 6/23/10—Microfluidics firm febit has announced a restructuring in order to focus on blood-based microRNA biomarker discovery, including collaborations and services for clinical researchers. The company’s workforce will be reduced by 60%. President and CEO Cord F. Staehler has resigned and was replaced by Hartmut Voss, PhD, and Jochen Kohlhaas, who will serve as co-CEOs. “The restructuring will allow febit to focus on its most successful business segment at the intersection of nanotechnology and future molecular diagnostics,” said Professor Christof Hettich, chairman of the Supervisory Board.
